drugset / Trial / NCT01361269
Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria
Phase 2
Unknown
100 enrolled
Zentopharm GmbH
Albert Schweitzer Hospital · collabCentro de Investigacao em Saude de Manhica · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Few efficient drugs for malaria treatment are available so far. Due to increased exposure of these drugs and due to the high risk of development of drug resistant strains of Plasmodium falciparum, new drug combinations have to be actively investigated. The investigators will test the efficiency, safety and tolerance of combined fosmidomycin and clindamycin treatment in acute uncomplicated malaria in children aged 3-10 years.
Timeline
- Start
- 2011-06
- Primary completion
- 2011-09
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clindamycin | Unknown | 10 mg/kg | Oral |
| Subject | Fosmidomycin | Small molecule | 30 mg/kg | Oral |